Conference Coverage
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dato-DXd Shows Tolerability Vs Chemo in HER2- Metastatic Breast Cancer
2
Rampal Analyzes Ropeginterferon Data in Low-Risk Polycythemia Vera
3
Ligufalimab Earns FDA Orphan Drug Designation in AML
4
New Targets Emerge for Aggressive Small Cell Lung Cancer
5
Blood Cancer Awareness Month: Advances in Lymphoma
Latest News
Shorts
0:29
Blood Cancer Awareness Month: Unmet Needs in Lymphoma
In recognition of September as Blood Cancer Awareness Month, Andrew Jallouk, MD, Vanderbilt University Medical Center, discusses the unmet needs in the treatment landscape of lymphoma.
a day ago
by
Andrew Jallouk, MD
0:19
Dr Poh: Considerations for Tafasitamab
In this episode of Targeted Treatment Tips, Christina Poh, MD, Fred Hutch Cancer Center, discusses the considerations physicians should keep in mind for the use of tafasitamab (Monjuvi) for the treatment of follicular lymphoma.
13 days ago
by
Christina Poh, MD
0:21
Vepdegestrant for ESR1-Mutant Breast Cancer: Safety and Tolerability
In an interview with Targeted Oncology, Erika Hamilton, MD, director, breast cancer research, Sarah Cannon Research Institute, discusses the safety and tolerability of vepdegestrant.
Earlier this month, the FDA accepted the new drug application for vepdegestrant, an investigational oral PROteolysis TArgeting Chimera (PROTAC), as a monotherapy for patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who have progressed on prior endocrine-based therapy. The Prescription Drug User Fee Act action date for the FDA's decision is set for June 5, 2026.
21 days ago
by
Erika P. Hamilton, MD
0:24
Funding Cancer Research
"So many of us in cancer research and oncology treatment chose these careers despite the opportunities for higher salaries, lower tuition costs and more immediate permanent employment. In order to continue to attract the brightest minds to the field, the question remains whether the administration and Congress can get together and recognize the favorable cost-benefit model of investing in biomedical research and the oncology enterprise."
Hear more from Robert Ferris, MD, PhD, UNC Lineberger Comprehensive Cancer Institute and editor-in-chief of Targeted Therapies in Oncology, in this month's Chief Insights in Oncology.
21 days ago
by
Robert L. Ferris, MD, PhD
1:01
A New Hope: Fighting Ovarian Cancer at its Weakest
Amir Jazaeri, MD, MD Anderson Cancer Center, explores a groundbreaking shift in cancer treatment strategy: targeting the disease when it's at its most vulnerable. Instead of waiting for a recurrence, a doctor explains why it makes more sense to identify high-risk patients and offer innovative clinical trials when the cancer cell count is at its lowest. Learn how new technology is helping to find microscopic disease that can't be seen on a CT scan and why this proactive approach could change the future of ovarian cancer treatment.
a month ago
by
Amir Jazaeri, MD
1:00
Talquetamab: The Perfect Bridge to CAR T?
Is there a way to safely get to CAR T-cell therapy while keeping aggressive cancer in check? In this video, Binod Dhakal, MD, Medical College of Wisconsin, explores how talquetamab can act as an effective and safe "bridging" therapy. He dives into how this sequential targeting approach could lead to better, more durable outcomes by fighting myeloma with two different antigens. Find out what makes a patient the perfect candidate for this strategy and how it's helping more people successfully receive life-changing CAR T treatment.
a month ago
by
Binod Dhakal, MD, MS
1:10
The Race Against Time: Why CAR T-Cell Therapy Isn't a Quick Fix
Binod Dhakal, MD, Medical College of Wisconsin, dives into the 2 biggest challenges of CAR T-cell therapy: the long manufacturing and wait times, and why that's a problem for patients with aggressive diseases. Discover how a rapidly relapsing disease can make CAR T-cell treatment less effective and lead to worse outcomes, highlighting the critical need for effective disease control before therapy.
a month ago
by
Binod Dhakal, MD, MS
0:18
Clinical Trial Limitations in MDS
Guillermo Garcia-Manero, MD, discusses the challenges in measuring quality of life in patients with myelodysplastic syndromes during medical trials. He discusses the difficulties faced when there is no placebo and the need for transfusions.
a month ago
by
Guillermo Garcia-Manero, MD
0:17
Impactful Survival Data from the COMMANDS Trial of Luspatercept in Low-Risk MDS
Guillermo Garcia-Manero, MD, MD Anderson Cancer Center, discusses the importance of survival data in making treatment decisions for patients. Garcia-Manero emphasizes how new data can influence the choice between standard of care and treatments that improve survival. It's a hopeful message for better decision-making in health care.
a month ago
by
Guillermo Garcia-Manero, MD
0:31
Dr Wen: Treatment Considerations for Dordaviprone in Diffuse Midline Glioma
In this episode of Targeted Treatment Tips, Dr Patrick Wen, Dana-Farber Cancer Institute, discusses some of the unique considerations clinicians should keep in mind when treating patients with dordaviprone (Modeyso), following its recent FDA approval in diffuse midline glioma. Dr Wen notes the agent's general tolerability and lack of notable adverse effects.
a month ago
by
Patrick Wen, MD
Podcasts
Advancing Prostate Cancer Treatment With Shared Decision-Making
In our first episode of Treating Together, Benjamin Garmezy, MD, and Ralph J. Miller Jr, MD, discuss multidisciplinary prostate cancer care.
Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning
Xiaojie Zhang, MD, and Akshat Singhal, PhD, discuss their research leveraging deep learning to predict how patients with ER+/HER2- breast cancer will respond to palbociclib.
BMT CTN 1902 in Myeloma: Key Findings With Garfall
In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.
Exploring Innovations in Lymphoma Treatment With Russler-Germain
David A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today.
Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.
Juneja Explores AI’s Impact in Early Cancer Detection and Treatment
In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.
How AI Is Revolutionizing Oncology in Diagnosis, Treatment, and Research
In this episode of Targeted Talks, Douglas Flora, MD, LSSBB, FACCC, discusses the transformative impact of artificial intelligence in oncology.
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Turning Inspiration Into Innovation: Hazim’s Impact on Oncology
Antonious Hazim, MD, shares insights on his journey into oncology, his experiences at the Mayo Clinic, and his ongoing research.
Kaklamani's Insights on the EMERALD Trial and Elacestrant in Advanced Breast Cancer
In this episode of Targeted Talks, Virginia Kaklamani, MD, DSc, discusses the background, findings, and implications of the phase 3 EMERALD trial.
Videos
COVID-19 Coverage
Targeted Oncology is actively following as the COVID-19 pandemic develops.
CAR T Cells and Beyond: An Exciting Future for Immunotherapy
While the volume and variety of information coming from current studies seems overwhelming, it is what is changing the cancer care environment today.
Precise Management of EGFR Exon 20-Positive Non–Small Cell Lung Cancer
For EGFR-positive disease with exon 20 insertions, methods used to treat the wide EGFR-positive population are not successful for these patients, calling for more targeted therapies.
Continuing Medical Education
All News
Advertisement
A phase 2 study reveals autologous TIL therapy's potential to stabilize recurrent head and neck cancer, offering hope for improved treatment options.
Discover the latest breakthroughs in oncology, including promising therapies for breast, lung, and bladder cancers, enhancing patient outcomes and hope.
Zipalertinib demonstrates significant efficacy and manageable safety in treating EGFR exon 20 insertion-mutated NSCLC, offering hope for patients.
Rezatapopt shows promising efficacy in treating various tumors with TP53 Y220C mutations, highlighting its potential as a groundbreaking cancer therapy.
A new study reveals that pembrolizumab and bevacizumab offer a promising, less toxic treatment for recurrent ovarian cancer, especially the clear cell subtype.
Neoadjuvant darovasertib showed promising tumor shrinkage in patients with uveal melanoma.
Dordaviprone gains NCCN approval as a promising treatment for recurrent H3 K27M-mutant diffuse glioma, addressing urgent patient needs.
Promising results emerge from a clinical trial combining IDE397 and sacituzumab govitecan for treating MTAP-deleted urothelial cancer, showcasing safety and efficacy.
BioAtla's ozuriftamab vedotin advances to phase 3 trials for HPV-positive oropharyngeal cancer, aiming for accelerated FDA approval amid rising incidence.
FDA accepts relacorilant and nab-paclitaxel for platinum-resistant ovarian cancer, showing promising survival benefits in recent trials.
Advertisement
ABBV-706 shows promising efficacy and manageable safety in relapsed/refractory small cell lung cancer, offering hope for heavily treated patients.
FDA fast tracks GLSI-100 for HER2-positive breast cancer, promising new hope for patients with unmet medical needs. Discover its potential benefits.
The FDA approves selumetinib for young patients with neurofibromatosis type 1, offering hope for effective treatment of inoperable tumors.
Nemvaleukin alfa shows promising antitumor activity in advanced melanoma and renal cell carcinoma, with manageable safety in heavily pretreated patients.
Firmonertinib shows significant antitumor activity in EGFR PACC-mutated NSCLC, with promising results in CNS penetration and manageable safety profiles.
The FDA approves Inlexzo, a groundbreaking treatment for bladder cancer, offering hope for patients unresponsive to traditional therapies.
FDA designates olomorasib and pembrolizumab as breakthrough therapy for advanced KRAS G12C-mutant lung cancer, showing promising response rates in trials.
Ifinatamab deruxtecan shows promising antitumor activity in extensive-stage small cell lung cancer, with high response rates and durable outcomes.
FDA grants orphan drug designation to BA-101, a promising treatment for glioblastoma, aiming to improve outcomes in this challenging cancer.
Osimertinib combined with chemotherapy significantly enhances overall survival in advanced EGFR-mutated non-small cell lung cancer, according to FLAURA2 trial results.
Interim results from the CAReS trial highlight ART27.13's potential to combat cancer-related weight loss, offering hope for effective treatment in CACS.
Pirtobrutinib shows significant promise in improving progression-free survival for patients with treatment-naive CLL/SLL, challenging traditional therapies.
A study reveals that azacitidine, especially in combination with ruxolitinib, improves survival in patients with advanced myeloproliferative neoplasms.
Discover the latest breakthroughs in oncology, including FDA approvals and promising therapies that offer hope for cancer patients and clinicians alike.
Rezolute streamlines the clinical pathway for ersodetug, expediting treatment for tumor hyperinsulinism and addressing urgent patient needs.
FDA fast-tracks CER-1236, a novel immunotherapy for acute myeloid leukemia, enhancing its development and potential market entry.
A groundbreaking study shows trastuzumab pamirtecan significantly improves progression-free survival in HER2-positive breast cancer patients, marking a major oncology advancement.
Lantern Pharma advances pediatric CNS cancer treatment with FDA guidance on LP-184 trial, targeting rare tumors and enhancing therapy with spironolactone.
Guardant Health's Shield test shows promising results in colorectal cancer screening, enhancing early detection and patient access with a noninvasive blood test.
Epcoritamab shows promise for outpatient treatment of relapsed DLBCL, enhancing patient access and quality of life while managing side effects effectively.
The FDA approves Bildyos and Bilprevda, expanding treatment options for osteoporosis and cancer-related bone loss, enhancing patient access and affordability.
Zongertinib receives FDA breakthrough therapy designation for treating HER2-mutant non-small cell lung cancer, promising new hope for patients.
The IOS-202/azacitidine combination revealed a complete response of 27.8% and an overall response rate of 66.7% in patients with chronic myelomonocytic leukemia.
Advertisement
Advertisement
